Washington University School of Medicine in St. Louis is launching an international clinical trial aimed at preventing Alzheimer’s disease in people genetically destined to develop the illness at a young age. Unlike most other Alzheimer’s prevention trials, this one will enroll people before the disease has taken hold — up to 25 years before the expected onset of dementia.
New Alzheimer’s prevention trial in young people
![Neurologist Eric McDade, DO, meets with Marty Reiswig, a participant in Alzheimer’s prevention trials at Washington University School of Medicine in St. Louis. Reiswig comes from a family with a genetic mutation that puts carriers at high risk of developing Alzheimer’s. McDade is the director of a new Alzheimer’s prevention trial involving young adults from high-risk families. The trial is evaluating whether an investigational drug can clear a key Alzheimer’s protein called amyloid beta and slow or stop the disease. (Photo: Matt Miller/School of Medicine)](https://neurology.wustl.edu/wp-content/uploads/2022/06/resized20211013_DIANTU_0268_forweb.jpeg)
View Content